About the Authors
Duke University School of Medicine, Durham, North Carolina, United States of America
Centro de Pesquisa de Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil
Instituto de Saúde Coletiva, Universidade Federal da Bahia, Salvador, Brazil
Bio-Manguinhos, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
Departamento de Medicina Clínica, Universidade de Pernambuco, Recife, Brazil
Chembio Diagnostic Systems, Medford, New York, United States of America
Yale University Schools of Public Health and Medicine, New Haven, Connecticut, United States of America
The authors have read the journal's policy and have the following conflicts: AIK and MGR are holders of the U.S. patent 8,124,110 for the proteins with repetitive bacterial-Ig-like (Big) domains present in Leptospira species used as antigens in the DPP assay. JE holds U.S. patent 7,879,597 for the dual path immunoassay device (DPP) evaluated in this study. JE, KPL, and RG are employees of Chembio Diagnostic Systems, Inc., which developed the DPP assay for leptospirosis and has transferred the DPP technology to the Brazilian Ministry of Health.
Conceived and designed the experiments: SAN GSR CLA DT KPL MAM AIK. Performed the experiments: SAN CLA DT AOD AHOG. Analyzed the data: SAN GSR KPL AIK. Contributed reagents/materials/analysis tools: DBMF RG JE KPL MGR MAM AIK. Wrote the paper: SAN GSR KPL. Reviewed and approved the final version of the manuscript: SAN GSR CLA DT AOD AHOG DBMF RG JE KPL MGR MAM AIK.